Taiwan News1d
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study
Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...
Business Wire4d
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...